<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="5a76eb85-8fbe-440d-a287-832e4e33aa53"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="Human Prescription Drug Label"/>
   <title>These highlights do not include all the information needed to use NITAZOXANIDE TABLETS safely and effectively. See full prescribing information for NITAZOXANIDE TABLETS.<br/> NITAZOXANIDE tablets, for oral use <br/> Initial U.S. Approval: 2002<br/>
   </title>
   <effectiveTime value="20250418"/>
   <setId root="c0dc0656-3c46-43f9-adea-5285c522cef8"/>
   <versionNumber value="8"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="116880195" root="1.3.6.1.4.1.519.1"/>
            <name>Rising Pharma Holdings, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="677604288" root="1.3.6.1.4.1.519.1"/>
                        <name>Suven Life Sciences</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="64980-526" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="c5d233a6-a56c-440c-b8b7-25745dca7d71"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20211118"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="64980-526" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Nitazoxanide</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Nitazoxanide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="500" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="SOA12P041N" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>NITAZOXANIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="SOA12P041N" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>NITAZOXANIDE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="AG9B65PV6B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="288VBX44JC" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (15000 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="6" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="64980-526-60" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20201127"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="12" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="64980-526-21" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20201127"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="18" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="64980-526-81" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20201127"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="64980-526-03" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20201127"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA213820" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20201127"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CV" code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="YELLOW"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CV" code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="PQ" unit="mm" value="13"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="INT" value="1"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">SUVEN;500</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="Section_1">
               <id root="27c8d971-0330-4946-bae2-e4db71d820e5"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Diarrhea caused by <content styleCode="italics">Giardia lamblia</content> or <content styleCode="italics">Cryptosporidium parvum:</content>
                     </content>
                     <br/> Nitazoxanide tablets (patients 12 years and older) are indicated for the treatment of diarrhea caused by <content styleCode="italics">Giardia lamblia</content> or <content styleCode="italics">Cryptosporidium parvum.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Limitations of Use</content>
                     <br/> Nitazoxanide tablets have not been shown to be effective for the treatment of diarrhea caused by <content styleCode="italics">Cryptosporidium parvum</content> in HIV-infected or immunodeficient patients <content styleCode="italics">[see <linkHtml href="#Section_14.2">Clinical Studies (14.2)</linkHtml>].</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250422"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Nitazoxanide tablets are antiprotozoal indicated for the treatment of diarrhea caused by <content styleCode="italics">Giardia lamblia or Cryptosporidium parvum </content>
                           <linkHtml href="#Section_1">(1).</linkHtml>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use:</content>
                           <br/> Nitazoxanide tablets have not been shown to be effective for the treatment of diarrhea caused by <content styleCode="italics">C. parvum</content> in HIV-infected or immunodeficient patients <linkHtml href="#Section_1">(1)</linkHtml>.</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_2">
               <id root="60754ddb-633f-4e6a-8392-f90d4601b1f8"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250422"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>• Nitazoxanide tablets should not be administered to pediatric patient 11 years of age or younger <linkHtml href="#Section_2.1">(2.1).</linkHtml>
                           <br/> • Dosage for treatment of diarrhea caused by <content styleCode="italics">G. lamblia</content> or <content styleCode="italics">C. parvum </content>
                           <linkHtml href="#Section_2.1">(2.1)</linkHtml>:</paragraph>
                        <br/>
                        <table cellspacing="0" cellpadding="0" border="0">
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">
                                       <br/>Age</content>
                                 </td>
                                 <td styleCode="Rrule" valign="top">
                                    <content styleCode="bold">
                                       <br/>Dosage</content>
                                 </td>
                                 <td styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Duration</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top">12 years and older<br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">One nitazoxanide tablet (500 mg nitazoxanide) every 12 hours with food <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">3 days<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_2.1">
                     <id root="24818ad3-0999-43aa-bfc2-a4d9a5a091b1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.1 Recommended Dosage and Important Administration Instructions</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Important Administration Instructions for Pediatric Patients 11 years of Age or Younger:</content>
                           <br/> Nitazoxanide tablets should not be administered to pediatric patients 11 years of age or younger because a single tablet contains a greater amount of nitazoxanide than the recommended dosing in this pediatric age group.<br/>
                           <content styleCode="bold">Table 1. Recommended Dosage</content>
                        </paragraph>
                        <paragraph/>
                        <table cellspacing="0" cellpadding="0">
                           <tbody>
                              <tr styleCode="Botrule First">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">
                                       <br/>Age</content>
                                 </td>
                                 <td styleCode="Rrule" valign="top">
                                    <content styleCode="bold">
                                       <br/>Dosage</content>
                                 </td>
                                 <td styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Duration</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top">12 years and older</td>
                                 <td styleCode="Rrule" valign="top">One Nitazoxanide tablet (500 mg nitazoxanide) taken orally every 12 hours with food</td>
                                 <td styleCode="Rrule" valign="top">3 days</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20250422"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_3">
               <id root="1f79c1bf-8406-478f-958b-99f07ef91142"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <effectiveTime value="20250422"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>• Nitazoxanide tablets: 500 mg <linkHtml href="#Section_3.1">(3.1)</linkHtml>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_3.1">
                     <id root="9d0b9478-ebd7-4420-b29d-1084cc9bc4a4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>3.1 Nitazoxanide Tablets (500 mg)</title>
                     <text>
                        <paragraph>Round, yellow colored film coated tablet, debossed with “SUVEN” on one side and “500” on the other side. Each tablet contains 500 mg of nitazoxanide.</paragraph>
                     </text>
                     <effectiveTime value="20250422"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_4">
               <id root="670fbbd1-947b-48af-8156-84fbf923af44"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <effectiveTime value="20250422"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Hypersensitivity <linkHtml href="#Section_4.1">(4.1)</linkHtml>
                        </paragraph>
                        <br/>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_4.1">
                     <id root="1cb6f180-86f6-4394-b379-9a43efa2bf53"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>4.1 Hypersensitivity</title>
                     <text>
                        <paragraph>Nitazoxanide tablets are contraindicated in patients with a prior hypersensitivity to nitazoxanide or any other ingredient in the formulations.</paragraph>
                     </text>
                     <effectiveTime value="20250422"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_6">
               <id root="feaea423-dbf5-43f0-8a56-ff08ae67fb14"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <effectiveTime value="20250422"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions in ≥2% of patients were abdominal pain, headache, chromaturia, and nausea <linkHtml href="#Section_6.1">(6.1)</linkHtml>.</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Rising Pharma Holdings, Inc. at 1-844-874-7464 or FDA at 1-800-FDA-1088 or </content>
                           <content styleCode="italics">
                              <content styleCode="bold">
                                 <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</linkHtml>
                              </content>
                           </content>
                           <content styleCode="bold">.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_6.1">
                     <id root="e44df673-aec5-4180-9522-f944e2e810e9"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.<br/>
                           <br/> The safety of nitazoxanide was evaluated in 2177 HIV-uninfected subjects 12 months of age and older who received nitazoxanide tablets or nitazoxanide for oral suspension at the recommended dose for at least three days. In pooled controlled clinical trials involving 536 HIV-uninfected subjects treated with nitazoxanide tablets or nitazoxanide for oral suspension, the most common adverse reactions were abdominal pain, headache, chromaturia and nausea (≥2%).<br/>
                           <br/> Safety data were analyzed separately for 280 HIV-uninfected subjects ≥12 years of age receiving nitazoxanide at the recommended dose for at least three days in 5 placebo-controlled clinical trials and for 256 HIV-uninfected subjects 1 through 11 years of age in 7 controlled clinical trials. There were no differences between the adverse reactions reported for nitazoxanide-treated subjects based upon age.</paragraph>
                     </text>
                     <effectiveTime value="20250422"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.2">
                     <id root="f7417fd2-f5f4-48f3-b9f8-662e169af171"/>
                     <code code="90375-7" codeSystem="2.16.840.1.113883.6.1" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post approval use of nitazoxanide. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following is a list of adverse reactions spontaneously reported with nitazoxanide tablets which were not included in clinical trial listings:<br/>
                           <br/>
                           <content styleCode="italics">Gastrointestinal disorders:</content> diarrhea, gastroesophageal reflux disease<br/>
                           <content styleCode="italics">Nervous System disorders:</content> dizziness<br/>
                           <content styleCode="italics">Respiratory, thoracic and mediastinal disorders:</content> dyspnea<br/>
                           <content styleCode="italics">Skin and subcutaneous tissue disorders:</content> rash, urticaria</paragraph>
                     </text>
                     <effectiveTime value="20250422"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_7">
               <id root="d2b69da6-2771-4f16-a5b1-74849216e9aa"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20250422"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Competition for binding sites may occur when administered concurrently with other highly plasma protein-bound drugs with narrow therapeutic indices. Monitor for adverse reactions <linkHtml href="#Section_7">(7)</linkHtml>.</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_7.1">
                     <id root="b1efca26-08e3-46f8-afa4-8f08f87df86a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>7.1 Highly Protein Bound Drugs with Narrow Therapeutic Indices</title>
                     <text>
                        <paragraph>Tizoxanide (the active metabolite of nitazoxanide) is highly bound to plasma protein (&gt;99.9%). Therefore, monitor for adverse reactions when administering nitazoxanide concurrently with other highly plasma protein-bound drugs with narrow therapeutic indices, as competition for binding sites may occur (e.g., warfarin).</paragraph>
                     </text>
                     <effectiveTime value="20250422"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_8">
               <id root="1d94244c-88e9-438d-b9ef-80fa9c4d6ab3"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250422"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Pediatric Patients: Safety and efficacy of ALINIA for Oral Suspension in pediatric patients less than one year of age has not been studied (<linkHtml href="#Section_8.4">8.4</linkHtml>).</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_8.1">
                     <id root="ed13a228-0a7d-4622-86de-cccad32162b6"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                           <br/> There are no data with nitazoxanide in pregnant women to inform a drug-associated risk. No teratogenicity or fetotoxicity was observed in animal reproduction studies with administration of nitazoxanide to pregnant rats and rabbits during organogenesis at exposures 30 and 2 times, respectively, the exposure at the maximum recommended human dose of 500 mg twice daily based on body surface area (BSA).<br/>
                           <br/> In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                           <br/>
                           <br/> Nitazoxanide was administered orally to pregnant rats at doses of 0, 200, 800 or 3200 mg/kg/day on gestation days 6 to 15. Nitazoxanide produced no evidence of systemic maternal toxicity when administered once daily via oral gavage to pregnant female rats at levels up to 3200 mg/kg/day during the period of organogenesis.</paragraph>
                        <paragraph>In rabbits, nitazoxanide was administered at doses of 0, 25, 50, or 100 mg/kg/day on gestation days 7 to 20. Oral treatment of pregnant rabbits with nitazoxanide during organogenesis resulted in minimal maternal toxicity and no external fetal anomalies.</paragraph>
                     </text>
                     <effectiveTime value="20250422"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.2">
                     <id root="31061571-2663-4026-9b94-e0b5ea53b20e"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                           <br/> No information regarding the presence of nitazoxanide in human milk, the effects on the breastfed infant, or the effects on milk production is available. The development and health benefits of breastfeeding should be considered along with the mother’s clinical need for nitazoxanide and any potential adverse effects on the breastfed infant from nitazoxanide or from the underlying maternal condition.</paragraph>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20250422"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.4">
                     <id root="cacfce37-2444-4881-9b8a-1dff20784be9"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and efficacy of ALINIA for Oral Suspension for the treatment of diarrhea caused by <content styleCode="italics">G. lamblia</content> or <content styleCode="italics">C. parvum</content> in pediatric patients 1 to 11 years of age has been established based on three (3) randomized, controlled studies with 104 pediatric subjects treated with ALINIA for Oral Suspension 100 mg/5 mL. Furthermore, the safety and efficacy of ALINIA for Oral Suspension for the treatment of diarrhea caused by<content styleCode="italics"> G. lamblia</content> or <content styleCode="italics">C. parvum</content> in pediatric patients 12 to 17 years of age has been established based on two (2) randomized controlled studies with 44 pediatric subjects treated with ALINIA for Oral Suspension 100 mg/5 mL. [<content styleCode="italics">see <linkHtml href="#Section_14.1">Clinical Studies (14.1)</linkHtml>
                           </content>]<br/>
                           <br/> The safety and efficacy of nitazoxanide tablets for the treatment of diarrhea caused by <content styleCode="italics">G. lamblia</content> or <content styleCode="italics">C. parvum</content> in pediatric patients 12 to 17 years of age has been established based on three (3) randomized controlled studies with 47 pediatric subjects treated with nitazoxanide tablets 500 mg.</paragraph>
                        <paragraph>A single nitazoxanide tablet contains a greater amount of nitazoxanide than is recommended for use in pediatric patients 11 years or younger. <content styleCode="italics">[see <linkHtml href="#Section_2.1">Dosage and Administration (2.1)</linkHtml>].</content>
                           <br/>
                           <br/> Safety and efficacy of ALINIA for Oral Suspension in pediatric patients less than one year of age has not been studied.</paragraph>
                     </text>
                     <effectiveTime value="20250422"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.5">
                     <id root="378289fb-bfcc-4551-908f-72d12c21999f"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies of nitazoxanide tablets and Alinia for oral suspension did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy in elderly patients should be considered when prescribing nitazoxanide tablets and Alinia for oral suspension.</paragraph>
                     </text>
                     <effectiveTime value="20250422"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.6">
                     <id root="4c401071-d0dc-45a2-88b2-83e387642d00"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>8.6 Renal and Hepatic Impairment</title>
                     <text>
                        <paragraph>The pharmacokinetics of nitazoxanide in patients with compromised renal or hepatic function has not been studied.</paragraph>
                     </text>
                     <effectiveTime value="20250422"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.7">
                     <id root="c04c64d3-4ab9-46fc-9b4e-9c8104a4ef3a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>8.7 HIV-Infected or Immunodeficient Patients</title>
                     <text>
                        <paragraph>Nitazoxanide tablets and Alinia for oral suspension have not been studied for the treatment of diarrhea caused by <content styleCode="italics">G. lamblia</content> in HIV-infected or immunodeficient patients. Nitazoxanide tablets and Alinia for oral suspension have not been shown to be superior to placebo for the treatment of diarrhea caused by <content styleCode="italics">C. parvum</content> in HIV-infected or immunodeficient patients <content styleCode="italics">[see <linkHtml href="#Section_14">Clinical Studies (14)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250422"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_10">
               <id root="8b8f7fb2-76ca-4483-b099-ed2d20e5ee2e"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>Limited information on nitazoxanide overdosage is available. In the event of overdose, gastric lavage may be appropriate soon after oral administration. Patients should be observed and given symptomatic and supportive treatment. There is no specific antidote for overdose with nitazoxanide. Because tizoxanide is highly protein bound (&gt;99.9%), dialysis is unlikely to significantly reduce plasma concentrations of the drug.</paragraph>
               </text>
               <effectiveTime value="20250422"/>
            </section>
         </component>
         <component>
            <section ID="Section_11">
               <id root="ff648643-8724-465a-96bb-16b52bc56517"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Nitazoxanide tablets contain the active ingredient, nitazoxanide, a synthetic antiprotozoal for oral administration. Nitazoxanide is a pale yellow to yellow crystalline powder. It is poorly soluble in ethanol and practically insoluble in water. Chemically, nitazoxanide is 2-acetyloxy-<content styleCode="italics">N</content>-(5-nitro-2-thiazolyl) benzamide. The molecular formula is C<sub>12</sub>H<sub>9</sub>N<sub>3</sub>O<sub>5</sub>S and the molecular weight is 307.3. The structural formula is:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM1"/>
                  </paragraph>
                  <paragraph>
                     <content>Nitazoxanide tablets contain 500 mg of nitazoxanide and the following inactive ingredients: maize starch, partially pregelatinized maize starch, sodium starch glycolate, hypromellose, talc, magnesium stearate, soy lecithin, polyvinyl alcohol, xanthan gum, titanium dioxide, D&amp;C Yellow No.10 Aluminum Lake, FD&amp;C Yellow No. 6 Aluminum Lake and FD&amp;C Blue No.2 Aluminum Lake.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250422"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>nitazoxanide-structure.jpg</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="nitazoxanide-structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_12">
               <id root="6dd18477-47e4-49f7-9441-858c8c7eb5ef"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250422"/>
               <component>
                  <section ID="Section_12.1">
                     <id root="b625e97c-0422-425f-b7ff-c9feb1dcebef"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Nitazoxanide is an antiprotozoal <content styleCode="italics">[see <linkHtml href="#Section_12.4">Microbiology (12.4)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250422"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_12.3">
                     <id root="5db8b3dd-6c1e-442b-a552-77123cd178f0"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                           <br/>
                           <content styleCode="italics">Single Dosing:</content>
                           <br/> Following oral administration of nitazoxanide tablets or oral suspension, the parent drug, nitazoxanide, is not detected in plasma. The pharmacokinetic parameters of the metabolites, tizoxanide and tizoxanide glucuronide are shown in Tables 2 and 3 below.<br/>
                           <br/>
                           <content styleCode="bold">Table 2. Mean (+/- SD) plasma pharmacokinetic parameters of tizoxanide and tizoxanide glucuronide following administration of a single dose of one 500 mg nitazoxanide tablet with food to subjects ≥12 years of age</content>
                        </paragraph>
                        <table width="800.66" cellspacing="0" cellpadding="0">
                           <colgroup>
                              <col width="14.2857142857143%"/>
                              <col width="14.2857142857143%"/>
                              <col width="14.2857142857143%"/>
                              <col width="14.2857142857143%"/>
                              <col width="14.2857142857143%"/>
                              <col width="14.2857142857143%"/>
                              <col width="14.2857142857143%"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule First">
                                 <td styleCode="Lrule Rrule" valign="top"/>
                                 <td styleCode="Rrule" colspan="3" valign="top">
                                    <content styleCode="bold">Tizoxanide</content>
                                 </td>
                                 <td styleCode="Rrule" colspan="3" valign="top">
                                    <content styleCode="bold">Tizoxanide Glucuronide</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Age</td>
                                 <td styleCode="Rrule" valign="top">C<sub>max</sub> (μg/mL)</td>
                                 <td styleCode="Rrule" valign="top">*T<sub>max</sub>
                                    <br/>(hr)</td>
                                 <td styleCode="Rrule" valign="top">AUC<sub>ԏ</sub>
                                    <br/>(μg•hr/mL)</td>
                                 <td styleCode="Rrule" valign="top">C<sub>max</sub>
                                    <br/>(μg/mL)</td>
                                 <td styleCode="Rrule" valign="top">*T<sub>max</sub>
                                    <br/>(hr)</td>
                                 <td styleCode="Rrule" valign="top">AUC<sub>ԏ</sub>
                                    <br/>(μg•hr/mL)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top">12-17 years<br/>≥18 years</td>
                                 <td styleCode="Rrule" valign="top">9.1 (6.1)<br/>10.6 (2.0)</td>
                                 <td styleCode="Rrule" valign="top">4.0 (1-4)<br/>3.0 (2-4)</td>
                                 <td styleCode="Rrule" valign="top">39.5 (24.2)<br/>41.9 (6.0)</td>
                                 <td styleCode="Rrule" valign="top">7.3 (1.9)<br/>10.5 (1.4)</td>
                                 <td styleCode="Rrule" valign="top">4.0 (2-8)<br/>4.5 (4-6)</td>
                                 <td styleCode="Rrule" valign="top">46.5 (18.2) <br/>63.0 (12.3)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>* T<sub>max</sub> is given as a Mean (Range)<br/>
                           <content styleCode="bold">Table 3. Mean (+/- SD) plasma pharmacokinetic of tizoxanide and tizoxanide glucuronide parameter values following administration of a single dose of nitazoxanide for oral suspension with food to subjects ≥1 year of age</content>
                        </paragraph>
                        <paragraph/>
                        <table width="799.33" cellspacing="0" cellpadding="0">
                           <colgroup>
                              <col width="11.3144758735441%"/>
                              <col width="11.6472545757072%"/>
                              <col width="12.9783693843594%"/>
                              <col width="11.8136439267887%"/>
                              <col width="13.9767054908486%"/>
                              <col width="12.9783693843594%"/>
                              <col width="11.8136439267887%"/>
                              <col width="13.477537437604%"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule First">
                                 <td styleCode="Lrule Rrule" colspan="2" valign="top"/>
                                 <td styleCode="Rrule" colspan="3" valign="top">
                                    <content styleCode="bold">
                                       <br/>Tizoxanide</content>
                                 </td>
                                 <td styleCode="Rrule" colspan="3" valign="top">
                                    <content styleCode="bold">
                                       <br/>Tizoxanide Glucuronide</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Age</td>
                                 <td styleCode="Rrule" valign="top">Dose</td>
                                 <td styleCode="Rrule" valign="top">C<sub>max</sub> (μg/mL)</td>
                                 <td styleCode="Rrule" valign="top">*T<sub>max</sub>(hr)</td>
                                 <td styleCode="Rrule" valign="top">AUC<sub>inf </sub>(μg•hr/mL)</td>
                                 <td styleCode="Rrule" valign="top">C<sub>max</sub> (μg/mL)</td>
                                 <td styleCode="Rrule" valign="top">*T<sub>max</sub>(hr)</td>
                                 <td styleCode="Rrule" valign="top">AUC<sub>inf </sub>(μg•hr/mL)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">1-3 years</td>
                                 <td styleCode="Rrule" valign="top">100 mg</td>
                                 <td styleCode="Rrule" valign="top">3.11 (2.0)</td>
                                 <td styleCode="Rrule" valign="top">3.5 (2-4)</td>
                                 <td styleCode="Rrule" valign="top">11.7 (4.46)</td>
                                 <td styleCode="Rrule" valign="top">3.64 (1.16)</td>
                                 <td styleCode="Rrule" valign="top">4.0 (3-4)</td>
                                 <td styleCode="Rrule" valign="top">19.0 (5.03)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">4-11 years</td>
                                 <td styleCode="Rrule" valign="top">200 mg</td>
                                 <td styleCode="Rrule" valign="top">3.00 (0.99)</td>
                                 <td styleCode="Rrule" valign="top">2.0 (1-4)</td>
                                 <td styleCode="Rrule" valign="top">13.5 (3.3)</td>
                                 <td styleCode="Rrule" valign="top">2.84 (0.97)</td>
                                 <td styleCode="Rrule" valign="top">4.0 (2-4)</td>
                                 <td styleCode="Rrule" valign="top">16.9 (5.00)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top">≥18 years</td>
                                 <td styleCode="Rrule" valign="top">500 mg</td>
                                 <td styleCode="Rrule" valign="top">5.49 (2.06)</td>
                                 <td styleCode="Rrule" valign="top">2.5 (1-5)</td>
                                 <td styleCode="Rrule" valign="top">30.2 (12.3)</td>
                                 <td styleCode="Rrule" valign="top">3.21 (1.05)</td>
                                 <td styleCode="Rrule" valign="top">4.0 (2.5-6)</td>
                                 <td styleCode="Rrule" valign="top">22.8 (6.49)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>* T<sub>max</sub> is given as a Mean (Range)<br/>
                           <content styleCode="italics">Multiple dosing:</content>
                           <br/> Following oral administration of a single nitazoxanide tablet every 12 hours for 7 consecutive days, there was no significant accumulation of nitazoxanide metabolites tizoxanide or tizoxanide glucuronide detected in plasma.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Bioavailability:</content>
                           <br/> Nitazoxanide for oral suspension is not bioequivalent to nitazoxanide tablets. The relative bioavailability of the suspension compared to the tablet was 70%.</paragraph>
                        <paragraph>When nitazoxanide tablets are administered with food, the AUC<sub>ԏ</sub> of tizoxanide and tizoxanide glucuronide in plasma is increased almost two-fold and the C<sub>max</sub> is increased by almost 50%.</paragraph>
                        <paragraph>When nitazoxanide for oral suspension was administered with food, the AUC<sub>ԏ</sub> of tizoxanide and tizoxanide glucuronide increased by about 45-50% and the C<sub>max</sub> increased by ≤10%.</paragraph>
                        <paragraph>Nitazoxanide tablets and nitazoxanide for oral suspension were administered with food in clinical trials and hence they are recommended to be administered with food [<content styleCode="italics">see <linkHtml href="#Section_2.1">Dosage and Administration (2.1)</linkHtml>
                           </content>].</paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                           <br/> In plasma, more than 99% of tizoxanide is bound to proteins.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                           <br/>
                           <content styleCode="italics">Metabolism</content>
                           <br/> Following oral administration in humans, nitazoxanide is rapidly hydrolyzed to an active metabolite, tizoxanide (desacetyl-nitazoxanide). Tizoxanide then undergoes conjugation, primarily by glucuronidation.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>
                           <br/> Tizoxanide is excreted in the urine, bile and feces, and tizoxanide glucuronide is excreted in urine and bile. Approximately two-thirds of the oral dose of nitazoxanide is excreted in the feces and one-third in the urine.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Pediatric Patients</content>
                           <br/> The pharmacokinetics of tizoxanide and tizoxanide glucuronide following administration of nitazoxanide tablets in pediatric patients 12-17 years of age are provided above in Table 2.Mean (±SD) plasma pharmacokinetic parameters of tizoxanide and tizoxanide glucuronide following administraton of a single dose of one 500 mg Nitazoxanide Tablet with food to subject ≥12 years of age. The pharmacokinetics of tizoxanide and tizoxanide glucuronide following administration of nitazoxanide for oral suspension in pediatric patients 1-11 years of age are provided above in Table 3. Mean (±SD) plasma pharmacokinetic of tizoxanide and tizoxanide glucuronide parameter values following administration of a single dose of ALINIA for Oral suspension with food to subjects ≥1 year of age.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug Interaction Studies</content>
                           <br/>
                           <content styleCode="italics">In vitro</content> studies demonstrated that tizoxanide has no significant inhibitory effect on cytochrome P450 enzymes.</paragraph>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20250422"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_12.4">
                     <id root="2934425f-f893-4e80-9207-0700e1360702"/>
                     <code code="49489-8" codeSystem="2.16.840.1.113883.6.1" displayName="MICROBIOLOGY SECTION"/>
                     <title>12.4 Microbiology</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Mechanism of Action</content>
                           <br/> The antiprotozoal activity of nitazoxanide is believed to be due to interference with the pyruvate:ferredoxin oxidoreductase (PFOR) enzyme-dependent electron transfer reaction which is essential to anaerobic energy metabolism. Studies have shown that the PFOR enzyme from <content styleCode="italics">G. lamblia</content> directly reduces nitazoxanide by transfer of electrons in the absence of ferredoxin. The DNA-derived PFOR protein sequence of <content styleCode="italics">C. parvum</content> appears to be similar to that of <content styleCode="italics">G. lamblia. </content>Interference with the PFOR enzyme-dependent electron transfer reaction may not be the only pathway by which nitazoxanide exhibits antiprotozoal activity. <br/>
                           <content styleCode="underline">
                              <br/> Resistance</content>
                           <br/> A potential for development of resistance by <content styleCode="italics">C. parvum</content> or <content styleCode="italics">G. lamblia</content> to nitazoxanide has not been examined.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Antimicrobial Activity</content>
                           <br/> Nitazoxanide and its metabolite, tizoxanide, are active <content styleCode="italics">in vitro</content> in inhibiting the growth of (i) sporozoites and oocysts of <content styleCode="italics">C. parvum</content> and (ii) trophozoites of <content styleCode="italics">G. lamblia.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Susceptibility Test Methods</content>
                           <br/> For protozoa such as <content styleCode="italics">C. parvum</content> and <content styleCode="italics">G. lamblia</content>, standardized tests for use in clinical microbiology laboratories are not available.</paragraph>
                     </text>
                     <effectiveTime value="20250422"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_13">
               <id root="2ad2ae42-c95d-4c15-9f8e-01e73a75dc22"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250422"/>
               <component>
                  <section ID="Section_13.1">
                     <id root="4dd50f4f-6d96-42e6-a2ab-bf043af616bb"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment Of Fertility</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Carcinogenesis</content>
                           <br/> Long-term carcinogenicity studies have not been conducted.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Mutagenesis</content>
                           <br/> Nitazoxanide was not genotoxic in the Chinese hamster ovary (CHO) cell chromosomal aberration assay or the mouse micronucleus assay. Nitazoxanide was genotoxic in one tester strain (TA 100) in the Ames bacterial mutation assay.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Impairment of Fertility</content>
                           <br/> Nitazoxanide did not adversely affect male or female fertility in the rat at 2400 mg/kg/day (approximately 20 times the clinical adult dose adjusted for body surface area).</paragraph>
                     </text>
                     <effectiveTime value="20250422"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_14">
               <id root="75d87817-af06-494a-acc7-e552a615aa2e"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20250422"/>
               <component>
                  <section ID="Section_14.1">
                     <id root="10ab3f9b-80ae-43b0-ad6d-5737c1dae96c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>14.1 Diarrhea Caused by <content styleCode="italics">G. lamblia</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">
                              <content styleCode="bold">Diarrhea caused by <content styleCode="italics">G. lamblia</content> in adults and adolescents 12 years of age or older:</content>
                           </content>
                           <br/> In a double-blind, controlled trial (Study 1) conducted in Peru and Egypt in adults and adolescents with diarrhea and with one or more enteric symptoms (e.g., abdominal pain, nausea, vomiting, fever, abdominal distention, loss of appetite, flatulence) caused by <content styleCode="italics">G. lamblia</content>, a three-day course of treatment with nitazoxanide tablets administered 500 mg twice daily was compared with a placebo tablet for 3 days. A third group of patients received open-label nitazoxanide for oral suspension administered 500 mg/25 mL of suspension twice daily for 3 days. A second double-blind, controlled trial (Study 2) conducted in Egypt in adults and adolescents with diarrhea and with or without enteric symptoms (e.g., abdominal colic, abdominal tenderness, abdominal cramps, abdominal distention, fever, bloody stool) caused by <content styleCode="italics">G. lamblia</content> compared nitazoxanide tablets administered 500 mg twice daily for 3 days to a placebo tablet. For both of these studies, clinical response was evaluated 4 to 7 days following the end of treatment. A clinical response of ‘well’ was defined as ‘no symptoms, no watery stools and no more than 2 soft stools with no hematochezia within the past 24 hours’ or ‘no symptoms and no unformed stools within the past 48 hours.’ The following clinical response rates were obtained:<br/>
                           <content styleCode="bold">Table 4. Adult and Adolescent Patients with Diarrhea Caused by <content styleCode="italics">G. lamblia </content>Clinical Response Rates* 4 to 7 Days Post-therapy <br/> % (Number of Successes/Total)</content>
                        </paragraph>
                        <table width="798" cellspacing="0" cellpadding="0">
                           <colgroup>
                              <col width="25%"/>
                              <col width="25%"/>
                              <col width="25%"/>
                              <col width="25%"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule First">
                                 <td styleCode="Lrule Rrule" valign="top"/>
                                 <td styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Nitazoxanide Tablets</content>
                                 </td>
                                 <td styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Nitazoxanide for Oral Suspension</content>
                                 </td>
                                 <td styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Placebo Tablets</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Study 1</td>
                                 <td styleCode="Rrule" valign="top">85% (46/54) <sup>¶ §</sup>
                                 </td>
                                 <td styleCode="Rrule" valign="top">83% (45/54) <sup>¶ §</sup>
                                 </td>
                                 <td styleCode="Rrule" valign="top">44% (12/27)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top">Study 2</td>
                                 <td styleCode="Rrule" valign="top">100% (8/8)</td>
                                 <td styleCode="Rrule" valign="top">-</td>
                                 <td styleCode="Rrule" valign="top">30% (3/10)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <sup>*</sup>Includes all patients randomized with <content styleCode="italics">G. lamblia</content> as the sole pathogen. Patients failing to complete the studies were treated as failures. <br/>
                           <sup>¶</sup>Clinical response rates statistically significantly higher when compared to placebo. <br/>
                           <sup>§</sup>The 95% confidence interval of the difference in response rates for the tablet and suspension is (-14%, 17%).<br/> Some patients with ‘well’ clinical responses had <content styleCode="italics">G. lamblia</content> cysts in their stool samples 4 to 7 days following the end of treatment. The relevance of stool examination results in these patients is unknown. Patients should be managed based upon clinical response to treatment.<br/>
                           <content styleCode="bold">
                              <content styleCode="underline">Diarrhea caused by <content styleCode="italics">G. lamblia</content> in pediatric patients 1 through 11 years of age:</content>
                           </content>
                           <br/> In a randomized, controlled trial conducted in Peru in 110 pediatric patients with diarrhea and with or without enteric symptoms (e.g., abdominal distention, right iliac fossa tenderness) caused by <content styleCode="italics">G. lamblia</content>, a three-day course of treatment with nitazoxanide (100 mg twice daily in pediatric patients ages 24-47 months, 200 mg twice daily in pediatric patients ages 4 through 11 years) was compared to a five-day course of treatment with metronidazole (125 mg twice daily in pediatric patients ages 2 through 5 years, 250 mg twice daily in pediatric patients ages 6 through 11 years). Clinical response was evaluated 7 to 10 days following initiation of treatment with a ‘well’ response defined as ‘no symptoms, no watery stools and no more than 2 soft stools with no hematochezia within the past 24 hours’ or ‘no symptoms and no unformed stools within the past 48 hours.’ The following clinical response rates were obtained:<br/>
                           <content styleCode="bold">Table 5. Clinical Response Rates in Pediatric Patients 7 to 10 Days Following Initiation of Therapy Intent-to-Treat and Per Protocol Analyses % (Number of Successes/Total), [95% Confidence Interval]</content>
                        </paragraph>
                        <table width="798" cellspacing="0" cellpadding="0">
                           <colgroup>
                              <col width="25%"/>
                              <col width="25%"/>
                              <col width="25%"/>
                              <col width="25%"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule First">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">Population</content>
                                 </td>
                                 <td styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Nitazoxanide (3 days)</content>
                                 </td>
                                 <td styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Metronidazole (5 days)</content>
                                 </td>
                                 <td styleCode="Rrule" valign="top">
                                    <content styleCode="bold">95% <content styleCode="italics">CI</content> Diff<sup>§</sup>
                                    </content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Intent-to-treat analysis<sup>†</sup>
                                 </td>
                                 <td styleCode="Rrule" valign="top">85% (47/55)</td>
                                 <td styleCode="Rrule" valign="top">80% (44/55)</td>
                                 <td styleCode="Rrule" valign="top">[-9%, 20%]</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top">Per protocol analysis<sup>¶</sup>
                                 </td>
                                 <td styleCode="Rrule" valign="top">90% (43/48)</td>
                                 <td styleCode="Rrule" valign="top">83% (39/47)</td>
                                 <td styleCode="Rrule" valign="top">[-8%, 21%]</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <sup>†</sup>Intent-to-treat analysis includes all patients randomized with patients not completing the study treated as failures.<br/>
                           <sup>¶</sup>Per protocol analysis includes only patients who took all of their medication and completed the study. Seven patients in each treatment group missed at least one dose of medication and one in the metronidazole treatment group was lost to follow-up.<br/>
                           <sup>§</sup>95% Confidence Interval on the difference in response rates (nitazoxanide-metronidazole).<br/> Some patients with ‘well’ clinical responses had <content styleCode="italics">G. lamblia</content> cysts in their stool samples 4 to 7 days following the end of treatment. The relevance of stool examination results in these patients is unknown. Patients should be managed based upon clinical response to treatment.</paragraph>
                     </text>
                     <effectiveTime value="20250422"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_14.2">
                     <id root="974fdea0-c84e-460b-85f1-df337ecf6517"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>14.2 Diarrhea Caused by <content styleCode="italics">C. parvum</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="underline">Diarrhea caused by <content styleCode="italics">C. parvum</content> in adults and adolescents 12 years of age or older:</content>
                           </content>
                           <br/> In a double-blind, controlled trial conducted in Egypt in adults and adolescents with diarrhea and with or without enteric symptoms (e.g., abdominal pain/cramps, nausea, vomiting) caused by <content styleCode="italics">C. parvum</content>, a three-day course of treatment with nitazoxanide tablets administered 500 mg twice daily was compared with a placebo tablet for 3 days. A third group of patients received open-label nitazoxanide for oral suspension administered 500 mg/25 mL of suspension twice daily for 3 days. Clinical response was evaluated 4 to 7 days following the end of treatment. A clinical response of ‘well’ was defined as ‘no symptoms, no watery stools and no more than 2 soft stools within the past 24 hours’ or ‘no symptoms and no unformed stools within the past 48 hours.’ The following clinical response rates were obtained:<br/>
                           <content styleCode="bold">Table 6. Clinical Response Rates in Adult and Adolescent Patients 4 to 7 Days Post-therapy % (Number of Successes/Total)</content>
                        </paragraph>
                        <table width="798" cellspacing="0" cellpadding="0">
                           <colgroup>
                              <col width="25%"/>
                              <col width="25%"/>
                              <col width="25%"/>
                              <col width="25%"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule First">
                                 <td styleCode="Lrule Rrule" valign="top"/>
                                 <td styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Nitazoxanide Tablets</content>
                                 </td>
                                 <td styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Nitazoxanide Suspension</content>
                                 </td>
                                 <td styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Placebo Tablets</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top">Intent-to-treat analysis*</td>
                                 <td styleCode="Rrule" valign="top">96% (27/28) <sup>¶ §</sup>
                                 </td>
                                 <td styleCode="Rrule" valign="top">87% (27/31) <sup>¶ §</sup>
                                 </td>
                                 <td styleCode="Rrule" valign="top">41% (11/27)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>*Includes all patients randomized with<content styleCode="italics"> C. parvum</content> as the sole pathogen. Patients failing to complete the study were treated as failures. <br/>
                           <sup>¶</sup>Clinical response rates statistically significantly higher when compared to placebo. <br/>
                           <sup>§</sup>The 95% confidence interval of the difference in response rates for the tablet and suspension is ( -10%, 28%).</paragraph>
                        <paragraph/>
                        <paragraph>In a second double-blind, placebo-controlled trial of nitazoxanide tablets conducted in Egypt in adults and adolescents with diarrhea and with or without enteric symptoms (e.g., abdominal colic, abdominal cramps, epigastric pain) caused by <content styleCode="italics">C. parvum</content> as the sole pathogen, clinical and parasitological response rates showed a similar trend to the first study. Clinical response rates, evaluated 2 to 6 days following the end of treatment, were 71% (15/21) in the nitazoxanide group and 42.9% (9/21) in the placebo group.<br/>
                           <br/> Some patients with ‘well’ clinical responses had <content styleCode="italics">C. parvum</content> oocysts in their stool samples 4 to 7 days following the end of treatment. The relevance of stool examination results in these patients is unknown. Patients should be managed based upon clinical response to treatment.<br/>
                           <br/>
                           <content styleCode="bold">
                              <content styleCode="underline">Diarrhea caused by <content styleCode="italics">C. parvum</content> in pediatric patients 1 through 11 years of age:</content>
                           </content>
                           <br/> In two double-blind, controlled trials in pediatric patients with diarrhea and with or without enteric symptoms (e.g., abdominal distention, colic, left iliac fossa tenderness) caused by <content styleCode="italics">C. parvum</content>, a three-day course of treatment with nitazoxanide (100 mg twice daily in pediatric patients ages 12-47 months, 200 mg twice daily in pediatric patients ages 4 through 11 years) was compared with a placebo. One study was conducted in Egypt in outpatients ages 1 through 11 years with diarrhea caused by <content styleCode="italics">C. parvum</content>. Another study was conducted in Zambia in malnourished pediatric patients admitted to the hospital with diarrhea caused by <content styleCode="italics">C. parvum</content>. Clinical response was evaluated 3 to 7 days post-therapy with a ‘well’ response defined as ‘no symptoms, no watery stools and no more than 2 soft stools within the past 24 hours’ or ‘no symptoms and no unformed stools within the past 48 hours.’ The following clinical response rates were obtained:<br/>
                           <content styleCode="bold">Table 7. Clinical Response Rates in Pediatric Patients 3 to 7 Days Post-therapy Intent-to-Treat Analyses % (Number of Successes/Total)</content>
                        </paragraph>
                        <table width="798" cellspacing="0" cellpadding="0">
                           <colgroup>
                              <col width="33.3333333333333%"/>
                              <col width="33.3333333333333%"/>
                              <col width="33.3333333333333%"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule First">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <content styleCode="bold">Population </content>
                                 </td>
                                 <td styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Nitazoxanide* </content>
                                 </td>
                                 <td styleCode="Rrule" valign="top">
                                    <content styleCode="bold">Placebo</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Outpatient Study, age 1 -11 years</td>
                                 <td styleCode="Rrule" valign="top">88% (21/24)</td>
                                 <td styleCode="Rrule" valign="top">38% (9/24)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top">Inpatient Study, Malnourished<sup>¶</sup>, age 12-35 months</td>
                                 <td styleCode="Rrule" valign="top">56% (14/25)</td>
                                 <td styleCode="Rrule" valign="top">23% (5/22)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <sup>*</sup>Clinical response rates statistically significantly higher compared to placebo. <br/>
                           <sup>¶</sup>60% considered severely underweight, 19% moderately underweight, 17% mild underweight.<br/> Some patients with ‘well’ clinical responses had <content styleCode="italics">C. parvum</content> oocysts in their stool samples 3 to 7 days following the end of treatment. The relevance of stool examination results in these patients is unknown. Patients should be managed based upon clinical response to treatment.<br/>
                           <content styleCode="bold">
                              <content styleCode="underline">Diarrhea caused by <content styleCode="italics">C. parvum</content> in Acquired Immune Deficiency Syndrome (AIDS) patients:</content>
                           </content>
                           <br/> A double-blind, placebo-controlled trial did not produce clinical cure rates that were significantly different from the placebo control when conducted in hospitalized, severely malnourished pediatric patients with acquired immune deficiency syndrome (AIDS) in Zambia. In this study, the pediatric patients received a three day course of nitazoxanide suspension (100 mg twice daily in pediatric patients ages 12-47 months, 200 mg twice daily in pediatric patients ages 4 through 11 years) and were evaluated for response four days after the end of treatment.</paragraph>
                     </text>
                     <effectiveTime value="20250422"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_17">
               <id root="03d46b3c-8579-4210-bdaa-d08deed66585"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20250422"/>
               <component>
                  <section ID="Section_17.1">
                     <id root="4f03508b-144b-46db-846a-bf441c745ff7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>16.1 Nitazoxanide Tablets (500 mg)</title>
                     <text>
                        <paragraph>Nitazoxanide tablets are round, yellow colored film coated tablet, debossed with “SUVEN” on one side and “500” on the other side. Each tablet contains 500 mg of nitazoxanide. The tablets are packaged in HDPE bottles of 6, 12, 18 and 30 tablets.</paragraph>
                        <paragraph/>
                        <table cellspacing="0" cellpadding="0">
                           <tbody>
                              <tr styleCode="Botrule First">
                                 <td styleCode="Lrule Rrule" valign="middle">Bottles of 6 tablets</td>
                                 <td styleCode="Rrule" valign="middle"> NDC 64980-526-60</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Bottles of 12 tablets</td>
                                 <td styleCode="Rrule" valign="middle">NDC 64980-526-21</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Bottles of 18 tablets</td>
                                 <td styleCode="Rrule" valign="middle">NDC 64980-526-81</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="middle">Bottles of 30 tablets </td>
                                 <td styleCode="Rrule" valign="middle">NDC 64980-526-03 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Store the tablets at 25°C (77°F); excursions permitted to 15°C-30°C (59°F-86°F). [See USP Controlled Room Temperature]</paragraph>
                     </text>
                     <effectiveTime value="20250422"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_16">
               <id root="32d8f30d-9c71-440a-9488-aa007db97e05"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise patients and parents/caregivers of pediatric patients taking nitazoxanide tablets of the following information:</paragraph>
                  <paragraph>
                     <content styleCode="underline">Dosage and Administration:</content>
                     <br/> Nitazoxanide tablets should be taken with food.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Drug-drug Interactions:</content>
                     <br/> Avoid concurrent warfarin use.</paragraph>
                  <paragraph>
                     <br/>
                     <content styleCode="bold">Manufactured by:</content>
                  </paragraph>
                  <paragraph>
                     <content>Suven Pharmaceuticals Limited</content>
                  </paragraph>
                  <paragraph>Pashamylaram, Telangana 502307, India</paragraph>
                  <paragraph>
                     <content styleCode="bold">Manufactured for:</content>
                     <br/> Rising Pharma Holdings, Inc.<br/> East Brunswick, NJ 08816<br/>
                     <br/> ALINIA for Oral Suspension is distributed by Lupin Pharmaceuticals, Inc. under license from Romark.<br/> ALINIA is a registered trademark of Romark<br/> ML No. 24/MD/AP/2009/F/CC</paragraph>
                  <paragraph>
                     <content styleCode="bold">Revised</content>: 03/2025<br/>
                     <br/> PIR52603-04</paragraph>
               </text>
               <effectiveTime value="20250422"/>
            </section>
         </component>
         <component>
            <section ID="Section_18">
               <id root="b0e96bd5-5cf9-45e7-9882-3667879b28cd"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>Rising<sup>®</sup>           NDC 64980-526-60</paragraph>
                  <paragraph>Nitazoxanide<br/>  Tablets<br/>  500 mg</paragraph>
                  <paragraph> 6 Tablets             Rx only</paragraph>
                  <paragraph>
                     <content>
                        <renderMultiMedia referencedObject="MM2"/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content>Rising</content>
                     <sup>®</sup>
                     <content>           NDC 64980-526-21</content>
                  </paragraph>
                  <paragraph>Nitazoxanide <br/>  Tablets<br/>  500 mg</paragraph>
                  <paragraph> 12 Tablets             Rx only</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM3"/>
                  </paragraph>
                  <paragraph>
                     <content>Rising</content>
                     <sup>®</sup>
                     <content>           NDC 64980-526-81</content>
                  </paragraph>
                  <paragraph>Nitazoxanide <br/>  Tablets<br/>  500 mg</paragraph>
                  <paragraph> 18 Tablets             Rx only</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM4"/>
                  </paragraph>
                  <paragraph>
                     <content>Rising® NDC 64980-526-03</content>
                  </paragraph>
                  <paragraph>Nitazoxanide<br/>Tablets<br/>500 mg</paragraph>
                  <paragraph>30 Tablets Rx only</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM5"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250422"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>nitazoxanide-6ct-label.jpg</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="nitazoxanide-6ct-label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM3">
                     <text>nitazoxanide-12ct-label.jpg</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="nitazoxanide-12ct-label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM4">
                     <text>nitazoxanide-18ct-label.jpg</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="nitazoxanide-18ct-label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM5">
                     <text>nitazoxanide-30ct-label.jpg</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="nitazoxanide-30ct-label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>